Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2011 by Taipei Medical University WanFang Hospital.
Recruitment status was  Recruiting
Information provided by:
Taipei Medical University WanFang Hospital Identifier:
First received: March 24, 2011
Last updated: March 25, 2011
Last verified: March 2011

The investigators would like to know the association of gene polymorphisms and metabolic adversities in clozapine-treated patients with schizophrenia in Taiwan.

Schizoaffective Disorder

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Effects of Gene Polymorphisms on Metabolic Features in Clozapine-treated Patients With Schizophrenia

Resource links provided by NLM:

Further study details as provided by Taipei Medical University WanFang Hospital:

Estimated Enrollment: 80
Study Start Date: May 2010
Estimated Study Completion Date: April 2011
Detailed Description:

The atypical antipsychotics, such as olanzapine, risperidone, quetiapine, and ziprasidone, are effective in treating both the positive and negative symptoms in schizophrenia (Kelleher et al., 2002). However, atypical antipsychotics have been linked to several forms of morbidity, including obesity, hyperlipidemia, and type 2 diabetes mellitus (DM) (Bergman and Ader, 2005; Jin et al., 2004; Melkersson and Dahl, 2004). Compared with the general population, life expectancy in schizophrenic patients is shorter by as much as 20%, attributable to higher rates of suicide, accidental deaths, and natural causes such as cardiovascular disease and DM (Harris and Barraclough, 1998). Several studies have suggested that these metabolic abnormalities may lead to a greater vulnerability to cardiovascular disease and thus may contribute to the excessive mortality among schizophrenic patients.


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

schizophrenia or schizoaffective disorder patients


Inclusion Criteria:

  • fulfilled DSM-IV criteria of schizophrenia or schizoaffective disorder
  • 18-65 year of age
  • receiving clozapine for at least 6 months

Exclusion Criteria:

  • diabetes mellitus patients
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01324167

Contact: Chun-Hsin Chen, MD 886-2-29307930 ext 53961

Taipei Medical University-WanFang Hospital Recruiting
Taipei, Taiwan
Contact: Chun-Hsin Chen, MD    886-2-29307930 ext 53961   
Sponsors and Collaborators
Taipei Medical University WanFang Hospital
Principal Investigator: Chun-Hsin Chen, MD Taipei Medical University WanFang Hospital
  More Information

No publications provided

Responsible Party: Chun-Hsin Chen, Department of Psychiatry, WanFang Hospital Identifier: NCT01324167     History of Changes
Other Study ID Numbers: 99037
Study First Received: March 24, 2011
Last Updated: March 25, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by Taipei Medical University WanFang Hospital:
schizoaffective disorder

Additional relevant MeSH terms:
Psychotic Disorders
Mental Disorders
Schizophrenia and Disorders with Psychotic Features processed this record on November 24, 2014